Synthetic affibody molecules: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors

Anna Orlova, Vladimir Tolmachev, Rikard Pehrson, Malin Lindborg, Thuy Tran, Mattias Sandström, Fredrik Y. Nilsson, Anders Wennborg, Lars Abrahmsén, Joachim Feldwisch

Research output: Contribution to journalArticlepeer-review

158 Citations (Scopus)

Abstract

The Affibody molecule ZHER2:342-pep2, site-specifically and homogeneously conjugated with a 1,4,7,10-tetra-azacylododecane-N,N′, N″,N‴-tetraacetic acid (DOTA) chelator, was produced in a single chemical process by peptide synthesis. DOTA-ZHER2:342-pep2 folds spontaneously and binds HER2 with 65 pmol/L affinity. Efficient radiolabeling with >95% incorporation of 111In was achieved within 30 min at low (room temperature) and high temperatures (up to 90°C). Tumor uptake of 111In-DOTA-ZHER2:342-pep2 was specific for HER2-positive xenografts. A high tumor uptake of 23% injected activity per gram tissue, a tumor-to-blood ratio of >7.5, and high-contrast gamma camera images were obtained already 1 h after injection. Pretreatment with Herceptin did not interfere with tumor targeting, whereas degradation of HER2 using the heat shock protein 90 inhibitor 17-allylaminogeldanamycin before administration of 111In-DOTA-ZHER2:342-pep2 obliterated the tumor image. The present results show that radiolabeled synthetic DOTA-ZHER2:342-pep2 has the potential to become a clinically useful radiopharmaceutical for in vivo molecular imaging of HER2-expressing carcinomas.

Original languageEnglish
Pages (from-to)2178-2186
Number of pages9
JournalCancer Research
Volume67
Issue number5
DOIs
Publication statusPublished - 1 Mar 2007
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Synthetic affibody molecules: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors'. Together they form a unique fingerprint.

Cite this